| Literature DB >> 28575045 |
Diana X Zhou1, Yinghong Zhao2, Jessica A Baker3, Qingqing Gu1,4, Kristin M Hamre3, Junming Yue5, Byron C Jones1, Melloni N Cook6, Lu Lu1,2.
Abstract
Alcohol consumption affects human health in part by compromising the immune system. In this study, we examined the expression of the Cd14 (cluster of differentiation 14) gene, which is involved in the immune system through a proinflammatory cascade. Expression was evaluated in BXD mice treated with saline or acute 1.8 g/kg i.p. ethanol (12.5% v/v). Hippocampal gene expression data were generated to examine differential expression and to perform systems genetics analyses. The Cd14 gene expression showed significant changes among the BXD strains after ethanol treatment, and eQTL mapping revealed that Cd14 is a cis-regulated gene. We also identified eighteen ethanol-related phenotypes correlated with Cd14 expression related to either ethanol responses or ethanol consumption. Pathway analysis was performed to identify possible biological pathways involved in the response to ethanol and Cd14. We also constructed a genetic network for Cd14 using the top 20 correlated genes and present several genes possibly involved in Cd14 and ethanol responses based on differential gene expression. In conclusion, we found Cd14, along with several other genes and pathways, to be involved in ethanol responses in the hippocampus, such as increased susceptibility to lipopolysaccharides and neuroinflammation.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28575045 PMCID: PMC5456352 DOI: 10.1371/journal.pone.0178689
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Primer sequences used for individual genes.
| Genes | Primer sequences |
|---|---|
| CD14 | |
| Aif1 | |
| CD68 | |
| IL18 | |
| Ly86 | |
| βactin | |
Fig 1Differential expression of the Cd14 gene across mouse strains rank ordered by expression levels.
The standard deviation and mean expression of Cd14 in each mouse is shown across the parent DBA/2J and C57BL/6J strains, F1 hybrids, and 67 BXD strains. The x-axis represents the mouse strain, with the y-axis as the mean gene expression using the log2 scale.
Fig 2Interval mapping for Cd14 was done using the Affymetrix dataset to identify significant eQTLs in the mouse genome.
The x-axis denotes a position on the mouse genome, in megabases (Mb), while the y-axis gives the likelihood ratio statistic scores (LRS), a measurement of the linkage between differences in Cd14 and differences in the region of the genome. The blue lines indicate the LRS values at a given position, with a significant LRS at 16.56 and suggestive LRS at 10.39. There was a significant eQTL on chromosome 18, around 36–37 Mb, and a suggestive eQTL on chromosome 13.
The single nucleotide polymorphisms (SNPs) of the Cd14 gene.
| SNP ID | Chr | Mb | Alleles | Gene | Exon | Function | B6 | D2 |
|---|---|---|---|---|---|---|---|---|
| wt37-18-36885521 | 18 | 36.885521 | C/T | Cd14 | 2 | Synonymous | C | T |
| rs8255713 | 18 | 36.885972 | T/A | Cd14 | 2 | Nonsynonymous | T | A |
| rs8255712 | 18 | 36.885973 | C/G | Cd14 | 2 | Nonsynonymous | C | G |
Two-way ANOVA analysis of CD14 expression.
| Source | df | Sums of Squares | Mean Square | F-ratio | Prob |
|---|---|---|---|---|---|
| Const | 1 | 2807.8 | 2807.8 | 815079 | 0.0001 |
| treatment | 1 | 0.046067 | 0.046067 | 13.373 | 0.0012 |
| strain | 25 | 0.42753 | 0.017101 | 4.9643 | 0.0001 |
| Error | 25 | 0.086121 | 0.003445 | ||
| Total | 51 | 0.559717 |
Top 20 Cd14 gene pathways.
| PathwayName | Number of Genes | Raw P value | Adjusted P value |
|---|---|---|---|
| MAPK signaling pathway | 25 | 2.57E-15 | 2.80E-13 |
| Focal Adhesion | 23 | 3.56E-12 | 1.94E-10 |
| Chemokine signaling pathway | 21 | 4.75E-11 | 1.29E-09 |
| Toll Like Receptor signaling | 17 | 3.69E-11 | 1.29E-09 |
| IL-6 signaling Pathway | 16 | 1.93E-09 | 4.21E-08 |
| MicroRNAs in cardiomyocyte hypertrophy | 15 | 2.79E-09 | 5.07E-08 |
| B Cell Receptor Signaling Pathway | 20 | 3.97E-09 | 5.80E-08 |
| Insulin Signaling | 18 | 4.26E-09 | 5.80E-08 |
| Apoptosis | 14 | 5.10E-09 | 6.18E-08 |
| IL-2 Signaling Pathway | 14 | 5.91E-09 | 6.44E-08 |
| IL-3 Signaling Pathway | 15 | 7.19E-09 | 7.12E-08 |
| IL-4 signaling Pathway | 12 | 3.97E-08 | 3.61E-07 |
| T Cell Receptor Signaling Pathway | 15 | 1.67E-07 | 1.40E-06 |
| IL-7 Signaling Pathway | 9 | 2.55E-07 | 1.99E-06 |
| Integrin-mediated cell adhesion | 12 | 5.93E-07 | 4.31E-06 |
| IL-5 Signaling Pathway | 11 | 7.23E-07 | 4.93E-06 |
| Alzheimers Disease | 10 | 2.08E-06 | 1.33E-05 |
| EGFR1 Signaling Pathway | 17 | 2.76E-06 | 1.67E-05 |
| Toll-like receptor signaling pathway | 7 | 8.10E-06 | 4.65E-05 |
| GPCRs, Class A Rhodopsin-like | 14 | 9.19E-06 | 5.00E-05 |
Fig 3The gene network of Cd14.
The 20 genes showed significant functional cohesion with a literature p value of8.10365e-17. Each node represents a gene, and each line between genes represents the cosine score of Latent Semantic Indexing (LSI), which is the functional coherence of gene sets.
Fig 4Gene expressions for Cd14, Ly86, Cd68 and Il18 in the ethanol and saline treated hippocampus were detected by quantitative RT-PCR.
Data were presented in relative expression level averaged from all 10 strains in ethanol and saline treated mice (*p<0.05, **p<0.01).
The phenotypes that are significantly correlated with alcohol.
| Record ID | Phenotype | N | P value | Authors |
|---|---|---|---|---|
| 18669 | Cell death in forebrain following exposure to ethanol at day 9 of gestation (E9), TUNEL-positive apoptotic cells (subtracted control maltose-dextranes counts) [cells/mm2]). | 18 | 0.018 | Balce, K. |
| 12635 | Anxiety assay (E5_NR), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), number of rears in the light side using a light-dark box in 8–12 week-old males during 5 min session [n beam breaks]. | 26 | 0.033 | Putman AH, and colleagues |
| 10988 | Anxiety assay after restraint stress (15 min) and an ethanol injection (1.8 g/kg ip), rearing events in the light side using a light-dark box by 8–12 week-old males during a 10 min session [n] | 26 | 0.036 | Putman AH, Miles MF |
| 10066 | Ethanol response (1.5 g/kg), blood ethanol concentration (BEC) normalization data set (BEC was stabilized to ~1.5 mg EtOH/ml blood using daily pyrazole injections) [mg/ml] | 23 | 0.003 | Crabbe JC |
| 10349 | Ethanol response (1.75 mg/kg ip), time to ataxia measured as loss of balance using a dowel test (Loss corresponds to BEC time 0) [min] | 27 | 0.026 | Kirstein SL, Davidson KL, Ehringer MA, Sikela JM, Erwin VG, Tabakoff B |
| 10089 | Ethanol response (2 g/kg ip), locomotor tolerance or sensitization in males, difference between activity after fourth ethanol trial and first trial [cm] | 19 | 0.025 | Cunningham CL |
| 11717 | Ethanol response (2.25 g/kg ip), motor coordination effects, difference in time on rotarod between training session and ethanol for females [sec] | 55 | 0.048 | Philip VM, Ansah TA, Blaha CD, Cook MN, Hamre KM, Lariviere WR, Matthews DB, Mittleman G, Goldowitz D, Chesler EJ |
| 18114 | Ethanol response (20% v/v) using the drinking in the dark (DID) method (4 hr access on day 4 of DID) to measure average baseline drinking under 5 weeks of normal housing [g/kg] | 15 | 0.035 | Jones BC, Lu L, Mormede P, Mulligan MK, Terenina E, Williams RW, Zhao W |
| 13566 | Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, baseline in chronic mild (CMS) stress group 1 week before start of 7 weeks of CMS (Ph | 13 | 0.017 | Jones BC, Lu Lu, Williams RW |
| 18108 | Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, difference between average alcohol consumption during first 5 weeks and last 4 weeks | 14 | 0.046 | Jones BC, Lu L, Mormede P, Mulligan MK, Terenina E, Williams RW, Zhao W |
| 15961 | Cell death in forebrain following exposure to ethanol at E9 (TUNEL+ cells/mm2) | 14 | 0.007 | Boyle, J. & Goldowitz, D. |
| 12970 | Ethanol response (chronic intermittent ethanol CIE cycles), 3a,5a-tetrahydroprogesterone (THP, allopregnanolone) in plasma 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males | 14 | 0.010 | Morrow AL, Lopez MF, Becker HC, Miles MF, Williams RW |
| 13022 | Ethanol response (CIE), 3a,5a-androsterone in blood plasma 3 days after cycle 5 of chronic intermittent ethanol vapor [pg/g] | 18 | 0.018 | Morrow, Lopez, Becker, Miles and Williams |
| 13019 | Ethanol response (CIE), 3a,5b-THP in blood plasma 3 days after cycle 5 of chronic intermittent ethanol (CIE) vapor treatment [pg/g] | 19 | 0.004 | Morrow, Lopez, Becker, Miles and Williams |
| 13027 | Ethanol response control, 3a,5a-tetrahydrodeoxycorticosterone (THDOC) in blood plasma 3 days after cycle 5 of chronic intermittent air vapor (CIE air control) [pg/g] | 15 | 0.032 | Morrow, Lopez, Becker, Miles and Williams |
| 13561 | Ethanol hepatocyte cytotoxicity response 9 hr after treatment (2.0 M), ratio of ethanol-induced release to maximal (lysis) lactate dehydrogenase (LDH) release, young adult male liver | 21 | 0.032 | Kaiser R, Hoynowski S, Williams RW, Scott RE |
| 16236 | Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 5 ng/ml TGF-beta + 0.6% ethanol, median in males [% LDH increase] | 21 | 0.045 | Liebe R, Hall RA, Williams RW, Dooley S, Lammert F |
| 17399 | Ethanol-induced conditioned taste aversion, saccharin intake during trials 2–4 after 4 g/kg ethanol injections (Group 4 g/kg) in 60 to 130-day-old males (from | 19 | 0.026 | Risinger FO, Cunningham CL |